The digital advertising specialist will announce its revenue for the third quarter.
The specialist in surgical technologies for lower extremity orthopedics will disclose first-quarter revenue.
The State has indicated that the tender offer on EDF’s minority shareholders will take place from 24 November to 22 December. The Autorité des Marchés Financiers (AMF) yesterday declared the simplified takeover bid project on EDF shares not yet held by the state compliant. The publication of the notice of the results of the offer by the MFA is scheduled for 28 December.
Eurazeo has announced that the Eurazeo Transition Infrastructure Fund (ETIF) has reached its first closing with €210m of commitments from the EIF and various institutional investors. The European Investment Fund invested €75 million, using resources from the European Investment Bank and InvestEU. In addition to Eurazeo’s commitment of €100 million, several institutional investors have made commitments to the fund.
LDC, which reported the half-yearly results, achieved a gross operating margin of 240.1 million euros against 198.3 million in the first half of the previous year, with an increase of 21%. It represents 8.8% of turnover for the period compared to 8.3% in the comparison period. Poultry, owner of the Loué, Le Gaulois but also Marie brands, recorded a current operating profit of 120.9 million euros (4.4% of turnover compared to 4.3% in the same period of the year). previous exercise).
The EIB and MedinCell sign a new €40 million loan agreement to support the development of innovative treatments. The new loan agreement between the European Investment Bank and the pharmaceutical company is intended to support the development of its portfolio of innovative treatments. This is already composed of several long-acting injectable products in the preclinical and clinical stages. An initial treatment using MedinCell’s technology, BEPO, is expected to reach the US market in the first half of 2023.
Predilife (specialist in innovative pathological risk prediction solutions for personalized medicine) announces the launch of Mammorisk tests at the Veneto Institute of Oncology. Located in Padua, the Institute is the Cancer Center of the Veneto Region. Wanting to offer a complete path from prevention to cure, the IOV has launched a tender in which Predilife was the winner. The Venetian institute will now open a consultation on breast cancer risk prediction based on this solution.
The spirit group will announce the results of the first semester.
In the first half of 2022-2023, which ended at the end of September, Soitec recorded a 28% increase in net profit to 95 million euros. During this period, the semiconductor materials specialist reported EBITDA from continuing operations of €167 million, up 22% and with a margin of 35.5%. It is slightly lower than in the first half of 2021-2022 when it stood at 36.8%.